|
US4837237A
(en)
|
1985-07-09 |
1989-06-06 |
Fred Hutchinson Cancer Research Center |
Therapy using glucosidase processing inhibitors
|
|
US5879680A
(en)
|
1987-12-23 |
1999-03-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cloned DNA for synthesizing unique glucocerebrosidase
|
|
US4985445A
(en)
|
1988-02-12 |
1991-01-15 |
Meiji Seika Kaisha, Ltd. |
Cancer cell metastasis inhibitors and novel compounds
|
|
US6451600B1
(en)
|
1989-12-22 |
2002-09-17 |
Genzyme Corporation |
Enzymatically active recombinant glucocerebrosidase
|
|
US5236838A
(en)
|
1988-12-23 |
1993-08-17 |
Genzyme Corporation |
Enzymatically active recombinant glucocerebrosidase
|
|
US5179023A
(en)
|
1989-03-24 |
1993-01-12 |
Research Corporation Technologies, Inc. |
Recombinant α-galactosidase a therapy for Fabry disease
|
|
US5011829A
(en)
|
1989-06-02 |
1991-04-30 |
G. D. Searle & Co. |
Pharmaceutical composition and method of inhibiting virus
|
|
US5103008A
(en)
|
1989-08-17 |
1992-04-07 |
Monsanto Company |
Compound, N-butyl-deoxynojirimycin-6-phosphate
|
|
US5401650A
(en)
|
1990-10-24 |
1995-03-28 |
The Mount Sinai School Of Medicine Of The City University Of New York |
Cloning and expression of biologically active α-galactosidase A
|
|
US5399567A
(en)
|
1993-05-13 |
1995-03-21 |
Monsanto Company |
Method of treating cholera
|
|
US6118045A
(en)
|
1995-08-02 |
2000-09-12 |
Pharming B.V. |
Lysosomal proteins produced in the milk of transgenic animals
|
|
US20020013953A1
(en)
|
1995-08-02 |
2002-01-31 |
Reuser Arnold J. |
Compositions and methods for treating enzyme deficiency
|
|
US20020073438A1
(en)
|
1995-08-02 |
2002-06-13 |
Reuser Arnold J. |
Methods of purifying human acid alpha-glucosidase
|
|
US6458574B1
(en)
|
1996-09-12 |
2002-10-01 |
Transkaryotic Therapies, Inc. |
Treatment of a α-galactosidase a deficiency
|
|
US6083725A
(en)
|
1996-09-13 |
2000-07-04 |
Transkaryotic Therapies, Inc. |
Tranfected human cells expressing human α-galactosidase A protein
|
|
US6210666B1
(en)
|
1997-10-21 |
2001-04-03 |
Orphan Medical, Inc. |
Truncated α-galactosidase A to treat fabry disease
|
|
JP2001522833A
(ja)
|
1997-11-10 |
2001-11-20 |
ジー・ディー・サール・アンド・カンパニー |
多剤耐性を治療するためのアルキル化イミノ糖類の使用
|
|
US6465488B1
(en)
|
1997-12-11 |
2002-10-15 |
Chancellor, Masters & Scholars Of The University Of Oxford |
Inhibition of glycolipid biosynthesis
|
|
US6274597B1
(en)
|
1998-06-01 |
2001-08-14 |
Mount Sinai School Of Medicine Of New York University |
Method of enhancing lysosomal α-Galactosidase A
|
|
DK2020438T3
(en)
|
1998-12-07 |
2018-07-23 |
Genzyme Corp |
Treatment of Pompe disease
|
|
ES2311921T3
(es)
|
1999-02-12 |
2009-02-16 |
United Therapeutics Corporation |
N-(8,8,8-trifluorooctil)1-5,-didesoxi-1,5-imino-d-glucitol para tratar infecciones por el virus de la hepatitis.
|
|
JP2003505430A
(ja)
|
1999-07-26 |
2003-02-12 |
ジー・ディー・サール・アンド・カンパニー |
デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
|
|
US6534300B1
(en)
|
1999-09-14 |
2003-03-18 |
Genzyme Glycobiology Research Institute, Inc. |
Methods for producing highly phosphorylated lysosomal hydrolases
|
|
US20020095135A1
(en)
|
2000-06-19 |
2002-07-18 |
David Meeker |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
|
US20040204379A1
(en)
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
|
US7056712B2
(en)
|
2000-07-18 |
2006-06-06 |
Duke University |
Treatment of glycogen storage disease type II
|
|
CN1638739A
(zh)
|
2000-08-18 |
2005-07-13 |
法玛西雅厄普约翰美国公司 |
治疗成瘾性障碍的化合物
|
|
US7001994B2
(en)
|
2001-01-18 |
2006-02-21 |
Genzyme Corporation |
Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
|
|
US7723296B2
(en)
|
2001-01-18 |
2010-05-25 |
Genzyme Corporation |
Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
|
|
EP1436316B1
(en)
|
2001-04-30 |
2008-01-23 |
ZyStor Therapeutics , Inc. |
Subcellular targeting of therapeutic proteins
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
CN1604788B
(zh)
|
2001-10-16 |
2013-04-17 |
里克斯金蒂克斯公司 |
高浓度蛋白制剂及其制备方法
|
|
US20030072761A1
(en)
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
|
US7658916B2
(en)
|
2002-04-05 |
2010-02-09 |
Genzyme Corporation |
Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
|
|
JP5589165B2
(ja)
|
2003-01-31 |
2014-09-17 |
マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー |
タンパク質欠損性障害の治療のための併用療法
|
|
FR2861991B1
(fr)
|
2003-11-07 |
2008-01-18 |
Centre Nat Rech Scient |
Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
|
|
US20080014188A1
(en)
|
2004-02-06 |
2008-01-17 |
Zankel Todd C |
Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof
|
|
DE602005020745D1
(de)
|
2004-02-10 |
2010-06-02 |
Zystor Therapeutics Inc |
Saure alpha-glukosidase und fragmente davon
|
|
US20060142234A1
(en)
|
2004-12-23 |
2006-06-29 |
Guohua Chen |
Injectable non-aqueous suspension
|
|
EP3782655A1
(en)
|
2005-05-17 |
2021-02-24 |
Amicus Therapeutics, Inc. |
A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
|
|
AU2007322123A1
(en)
|
2006-11-13 |
2008-05-29 |
Biomarin Pharmaceutical Inc. |
Methods for treating Pompe disease
|
|
CN102978185B
(zh)
|
2007-01-18 |
2015-02-11 |
建新公司 |
包含氨基氧基基团的寡糖及其轭合物
|
|
EP2155197A4
(en)
|
2007-03-09 |
2011-10-12 |
Link Medicine Corp |
TREATMENT OF LYSOSOMAL STORAGE DISEASES
|
|
AU2008245578A1
(en)
|
2007-04-26 |
2008-11-06 |
Amicus Therapeutics, Inc. |
Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
|
|
US20100317690A1
(en)
|
2007-11-21 |
2010-12-16 |
Summit Corporation Plc |
Treatment of protein folding disorders
|
|
WO2009075815A1
(en)
|
2007-12-07 |
2009-06-18 |
Duke University |
Immunomodulating gene therapy
|
|
WO2009102895A2
(en)
|
2008-02-12 |
2009-08-20 |
Amicus Therapeutics, Inc. |
Method to predict response to pharmacological chaperone treatment of diseases
|
|
AU2009223125A1
(en)
|
2008-03-12 |
2009-09-17 |
Amicus Therapeutics, Inc. |
Assays for diagnosing and evaluating treatment options for Pompe disease
|
|
JP2011512876A
(ja)
|
2008-03-12 |
2011-04-28 |
アミカス セラピューティックス インコーポレイテッド |
特異的薬理シャペロンを用いたポンペ病の治療および代理マーカーを用いた治療の監視
|
|
WO2009137721A2
(en)
|
2008-05-07 |
2009-11-12 |
Zystor Therapeutics, Inc. |
Lysosomal targeting peptides and uses thereof
|
|
US20110237538A1
(en)
|
2008-08-06 |
2011-09-29 |
Summit Corporation Plc |
Treatment of lysosomal storage disorders and other proteostatic diseases
|
|
WO2010056746A1
(en)
|
2008-11-11 |
2010-05-20 |
Amicus Therapeutics, Inc. |
Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
|
|
EP3608330B1
(en)
|
2008-12-16 |
2022-11-09 |
Genzyme Corporation |
Synthetic intermediates for preparing oligosaccharide-protein conjugates
|
|
WO2010096369A1
(en)
|
2009-02-18 |
2010-08-26 |
Amicus Therapeutics, Inc. |
Mouse model for pompe disease and methods of use thereof
|
|
JP5645918B2
(ja)
|
2009-04-09 |
2014-12-24 |
アミカス セラピューティックス インコーポレイテッド |
リソソーム蓄積障害の予防および／または治療方法
|
|
EP2435459B1
(en)
|
2009-05-26 |
2016-05-04 |
Amicus Therapeutics, Inc. |
Utilization of pharmacological chaperones to improve manufacturing and purification of acid beta-glucosidase
|
|
US8785168B2
(en)
|
2009-06-17 |
2014-07-22 |
Biomarin Pharmaceutical Inc. |
Formulations for lysosomal enzymes
|
|
KR102000383B1
(ko)
|
2009-09-29 |
2019-07-15 |
유니버시테이트 젠트 |
만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
|
|
US9427033B2
(en)
|
2009-12-16 |
2016-08-30 |
Under Armour, Inc. |
Athletic arm warmer
|
|
US20130196410A1
(en)
|
2010-03-05 |
2013-08-01 |
Alnylam Pharmaceuticals, Inc |
Compositions and methods for modifying the glycosylation pattern of a polypeptide
|
|
BR112013007616B1
(pt)
|
2010-09-29 |
2023-01-24 |
Oxyrane Uk Limited |
Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero
|
|
SG10201605874TA
(en)
|
2011-04-22 |
2016-09-29 |
Genzyme Corp |
Modified acid alpha glucosidase with accelerated processing
|
|
WO2013013017A2
(en)
|
2011-07-21 |
2013-01-24 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
|
|
JP6180423B2
(ja)
*
|
2011-11-08 |
2017-08-16 |
ユニヴァーシティ オブ ワシントン |
リソソーム酵素アッセイ法および組成物
|
|
WO2013091897A1
(en)
|
2011-12-22 |
2013-06-27 |
Centogene Gmbh |
Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
|
|
KR20200032244A
(ko)
|
2012-03-07 |
2020-03-25 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
|
|
CA2867237C
(en)
|
2012-03-15 |
2024-01-02 |
Wouter Vervecken |
Methods and materials for treatment of pompe's disease
|
|
RS61598B1
(sr)
*
|
2012-05-03 |
2021-04-29 |
Amicus Therapeutics Inc |
Režimi doziranja za tretman pompeove bolesti
|
|
US20150147309A1
(en)
|
2012-06-06 |
2015-05-28 |
Fondazione Telethon |
Allosteric chaperones and uses thereof
|
|
AU2014205378B2
(en)
|
2013-01-09 |
2018-08-30 |
Amicus Therapeutics, Inc. |
Stable parenteral DNJ compositions
|
|
PT3086784T
(pt)
|
2013-12-23 |
2019-06-27 |
Bcn Peptides Sa |
Análogos de bicalutamida ou (s)-bicalutamida como compostos ativadores de exocitose para utilização no tratamento de um distúrbio de armazenamento lisossómico ou glicogenose
|
|
JP6851964B2
(ja)
*
|
2014-09-30 |
2021-03-31 |
アミカス セラピューティックス インコーポレイテッド |
炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
|
|
WO2017049161A1
(en)
*
|
2015-09-18 |
2017-03-23 |
Duke University |
ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER
|
|
IL299470B2
(en)
*
|
2015-12-30 |
2026-05-01 |
Amicus Therapeutics Inc |
Improved acid alpha-glucosidase for the treatment of Pompe disease
|
|
CA3019354A1
(en)
|
2016-03-30 |
2017-10-05 |
Amicus Therapeutics, Inc. |
Method for selection of high m6p recombinant proteins
|
|
KR102618519B1
(ko)
|
2016-03-30 |
2023-12-28 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
재조합 산 알파-글루코시다제를 포함하는 제형
|